Overview

Utrogestan Versus Nifedipine as Tocolysis for Preterm Labor: a Randomised Controlled Trial

Status:
Unknown status
Trial end date:
2014-10-01
Target enrollment:
0
Participant gender:
Female
Summary
RESEARCH HYPOTHESIS -Incidence of preterm delivery is lower in women treated with oral micronized progesterone (Utrogestan) as acute tocolysis agent compare to Nifedipine group with fewer maternal side effect
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
nor zila hassan malek
Treatments:
Nifedipine
Progesterone
Criteria
Inclusion Criteria:

• Singleton pregnancy women between 22 and 34 weeks of gestation who presented with
threatened preterm labor.

Exclusion Criteria:

- Multiple pregnancies

- Women with Preterm Prelabour Rupture of Membrane

- Fetal death

- Women with bad obstetric history

- Women with history of cervical incompetence

- Contraindication to Nifedipine such as cardiovascular disease, hyperthyroidism, severe
pre eclampsia or to Utrogestan

- Maternal or fetal indication for immediate delivery, such as fetal distress, bleeding
placenta previa, abruption placenta

- Contraindication for tocolysis, for example severe pre eclampsia, intrauterine growth
restriction, fetal anomaly, chorioamnionitis, significant antepartum haemorrhage

- Cervical dilatation of 3cm or more

- Patients with previous tocolytic treatment during this pregnancy

- Women who refuse to participate in this study